ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
Neurodevelopmental Impacts of Ketamine and Alfaxalone Anesthesia Evaluated with Mouse MRI.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Injectable anesthetics are commonly used in murine experimental procedures. However, these agents may result in neurotoxicity, which should be considered in interpretation of experimental results. We evaluated acute effects of 2 different anesthetic combinations on juvenile mouse brain development using structural MRI to assess impact on the brain. We compared the use of ketamine-xylazine, a commonly used injectable anesthetic combination in mice, to alfaxalone-xylazine in the context of noninvasive procedures requiring immobilization (that is, not a surgical plane of anesthesia). In this longitudinal study, we used MRI to produce three-dimensional scans of mouse brains at 2 time points (postnatal days 14 and 23), analogous to early childhood to prepubescence in humans. At postnatal day 16, mice were either dosed with ketamine-xylazine, alfaxalone-xylazine, or left untreated. From the scans, we quantified whole brain and structure volumes across the brain, comparing growth between time points and modeling the effect of both anesthetics compared with controls. Anesthetic parameters were measured, and general health and welfare were monitored during and after each injectable anesthesia drug condition. Results indicate that systemic and brain toxicity were reduced in mice treated with alfaxalone-xylazine compared with ketamine-xylazine. In addition, both ketamine-xylazine and alfaxalone-xylazine reliably anesthetized all mice, although mice administered ketamine-xylazine showed increased weight loss compared with the alfaxalone-xylazine in the postanesthetic period. These findings highlight alfaxalone-xylazine as a convenient and possibly safer alternative anesthetic for mouse brain development studies when compared with ketamine-xylazine and as a viable option as an injectable anesthetic in juvenile mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.